TR200806302A2 - Solubility and stability enhancing pharmaceutical formulation. - Google Patents

Solubility and stability enhancing pharmaceutical formulation.

Info

Publication number
TR200806302A2
TR200806302A2 TR2008/06302A TR200806302A TR200806302A2 TR 200806302 A2 TR200806302 A2 TR 200806302A2 TR 2008/06302 A TR2008/06302 A TR 2008/06302A TR 200806302 A TR200806302 A TR 200806302A TR 200806302 A2 TR200806302 A2 TR 200806302A2
Authority
TR
Turkey
Prior art keywords
solubility
pharmaceutical formulation
stability enhancing
enhancing pharmaceutical
stability
Prior art date
Application number
TR2008/06302A
Other languages
Turkish (tr)
Inventor
Bi̇lgi̇ç Mahmut
Original Assignee
Bi̇lgi̇ç Mahmut
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bi̇lgi̇ç Mahmut filed Critical Bi̇lgi̇ç Mahmut
Priority to TR2008/06302A priority Critical patent/TR200806302A2/en
Priority to PCT/TR2009/000109 priority patent/WO2010021609A1/en
Publication of TR200806302A2 publication Critical patent/TR200806302A2/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A61K31/366—Lactones having six-membered rings, e.g. delta-lactones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/397—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having four-membered rings, e.g. azetidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin

Abstract

Mevcut buluş, çözünürlük sorunu olan bir aktif maddeyi stabilite sorunu olan bir terapötik ajanla kombinasyon halinde içeren farmasötik formülasyonlara, bunların hazırlanma yöntemlerine ve tıbbi kullanımlarına ilişkindir.The present invention relates to pharmaceutical formulations, methods of preparation and medical uses comprising an active substance having a solubility problem in combination with a therapeutic agent having a stability problem.

TR2008/06302A 2008-08-22 2008-08-22 Solubility and stability enhancing pharmaceutical formulation. TR200806302A2 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
TR2008/06302A TR200806302A2 (en) 2008-08-22 2008-08-22 Solubility and stability enhancing pharmaceutical formulation.
PCT/TR2009/000109 WO2010021609A1 (en) 2008-08-22 2009-08-24 Solubility and stability enhancing pharmaceutical formulation

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
TR2008/06302A TR200806302A2 (en) 2008-08-22 2008-08-22 Solubility and stability enhancing pharmaceutical formulation.

Publications (1)

Publication Number Publication Date
TR200806302A2 true TR200806302A2 (en) 2010-03-22

Family

ID=41396995

Family Applications (1)

Application Number Title Priority Date Filing Date
TR2008/06302A TR200806302A2 (en) 2008-08-22 2008-08-22 Solubility and stability enhancing pharmaceutical formulation.

Country Status (2)

Country Link
TR (1) TR200806302A2 (en)
WO (1) WO2010021609A1 (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011002424A2 (en) * 2009-07-02 2011-01-06 Bilgic Mahmut Solubility and stability enchancing pharmaceutical formulation

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR040588A1 (en) * 2002-07-26 2005-04-13 Schering Corp PHARMACEUTICAL FORMULATION INCLUDING AN INHIBITOR OF CHOLESTEROL ABSORPTION AND AN INHIBITOR OF A HMGCO TO REDUCTASE
WO2006134604A1 (en) * 2005-06-15 2006-12-21 Hetero Drugs Limited Combination composition of cholesterol absorption inhibitor and 3-hydroxy-3-methylglutaryl-coenzyme a (hmg-coa) reductase inhibitor
EP1741427A1 (en) * 2005-07-06 2007-01-10 KRKA, D.D., Novo Mesto Pharmaceutical composition comprising simvastatin and ezetimibe
EP1905424A3 (en) * 2006-02-02 2008-04-30 Ranbaxy Laboratories Limited Process for the preparation of a pharmaceutical composition comprising stabilized statin particles
EP2120882A2 (en) * 2007-02-23 2009-11-25 Krka Pharmaceutical composition containing a cholesterol absorption inhibitor

Also Published As

Publication number Publication date
WO2010021609A1 (en) 2010-02-25

Similar Documents

Publication Publication Date Title
CY1119616T1 (en) HUMAN ANTI-DUMP DRUG CONSUMPTION AGAINST TISSUE
TR200806298A2 (en) Pharmaceutical formulation
CY2017018I1 (en) PREPARATION OF ACTIVE, HIGHLY PHOSPHORYLATED, HUMAN LYSOSOMIC SULFATASE ENZYMES AND USES THEREOF
ECSP109917A (en) NEW DERIVATIVES OF AZABIFENILAMINOBENZOIC ACID
ATE471144T1 (en) INTRANASAL ADMINISTRATION OF RAPID-ACTING INSULIN
WO2010110685A3 (en) Pyrimidinyl and 1,3,5-triazinyl benzimidazole sulfonamides and their use in cancer therapy
EA201201050A1 (en) PYRAZOLES AS AN ANTAGONISTS CRTH2
EA201390799A1 (en) TRIAZOLOPRYRIDINS
TR200900878A2 (en) Pharmaceutical formulations combined in a single dosage form
CY1117174T1 (en) USE OF 24-norUDCA FOR TREATMENT OF US CHOLOGICAL DISEASES
CY1109537T1 (en) Peptides and Peptide Derivatives, PREPARATION OF THESE ALSO USE THESE FOR THE PREPARATION OF THERAPEUTIC AND / OR PREVENTIVE ACTIVE ACTION
CY1115961T1 (en) ORVEPITANT MALEATE ANHYDRATED FORM OF CRYSTAL MALINE
PT2459153E (en) Pharmaceutical or cosmetic or dietetic composition for promoting a hair pigmentation effect
MX2009012782A (en) Formulations for the oral administration of therapeutic agents and related methods.
TR200806300A2 (en) Solubility enhancing pharmaceutical formulation
WO2011002422A3 (en) Solubility enhancing pharmaceutical formulation
UY31839A (en) COMPOUNDS
TR200900879A2 (en) Pharmaceutical compositions in which the active ingredients are combined in a single dosage form
BRPI0910570A2 (en) use of bioconjugates and pharmaceutical formulations
MX2010008365A (en) Sustained release formulation comprising octreotide and three linear polylactide-co-glycolide polymers.
TR201803451T4 (en) OLMESARTAN FORMULATIONS.
TR200806302A2 (en) Solubility and stability enhancing pharmaceutical formulation.
BR112012016736A2 (en) composition, pharmaceutical formulation and use of composition "
IN2014DN10134A (en)
JP2009292763A5 (en)